CRYOPDP, a cryoport company, receives the 2021 Europe Bioprocess Excellence Award from IMAPAC | State
NASHVILLE, Tennessee., Oct.29, 2021 / PRNewswire / – Cryoport, Inc. (NASDAQ: CYRX) (“Cryoport” or the “Company”), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced that its operating company wholly owned, CRYOPDP, one of the world’s leading providers of innovative temperature-controlled logistics solutions for the clinical research, biopharmaceutical, and cell and gene therapy markets, headquartered at Paris, France was recognized as the winner of the “The company you must watch in 2022” award at the Europe Bioprocessing Excellence Awards 2021. The virtual award ceremony organized jointly with the Biologics Contract Manufacturing Europe 2021 and 4e Biologics World Nordic 2021 on 28 October 2021 brought together more than 800 guests representing more than 150 organizations within Europe in 30 different categories of organic product manufacturing.
The Europe Bioprocessing Excellence Awards aim to recognize outstanding bioprocessing experts, organizations and technologies that facilitate bioproduction excellence at increased speed, lower cost and higher quality. Showcasing the best leaders in the bioprocess and biofabrication industry, along with the latest technological advancements and best manufacturing practices, the Europe Bioprocessing Excellence Awards salute today’s extraordinary leaders and trendsetters and inspire innovators from tomorrow.
CRYOPDP is located in 23 global facilities in 14 countries and has over 25 years of experience serving the life science and health industries, providing customized, turnkey, high-end logistics and transportation solutions, with over 300,000 high-value critical annual shipments worldwide. CRYOPDP covers an important part of the temperature-controlled healthcare supply chain, including high-end services, packaging, prep kit preparation and specialist courier support, as well as solutions to high-end added value such as LabMove, DtP and Control Tower, fully integrated project management. Solution.
“We are touched and grateful for this prestigious award, recognized as’ the company to watch in 2022″, said Cedric Picaud, CEO of CRYOPDP. “It is a great honor for the company to take on this role and it says a lot about our remarkable team and the work they do to fulfill our mission to improve the health of people around the world.”
Jerrell shelton, President and CEO of Cryoport, added, “As Cryoport continues to grow and evolve, we have focused on providing the highest quality solutions and services to our global customers. This award is a testament to our innovation and expertise in bioprocesses and biofabrication, our cutting-edge logistics solutions for the life sciences industry, and our team’s dedication and commitment to exceed the industry’s competitive benchmarks. “
Cryoport, Inc. (Nasdaq: CYRX) is a global leader in temperature-controlled supply chain solutions for the life sciences industry supporting life-saving cell and gene therapies across the clinical and commercial spectrum. With 33 strategic locations covering the Americas, EMEA (Europe, the Middle East and Africa) and APAC (Asia Pacific), Cryoport’s global platform consists of a family of companies (Cryoport Systems, MVE Biological Solutions, CRYOPDP and CRYOGENE), which provide solutions, services and essential products to more than 2000 customers active in the field of biopharmacy, reproductive medicine and animal health around the world. Cryoport is the world’s largest manufacturer of cryogenic equipment and the world’s third-largest specialist courier for the life science industry. From June 30, 2021, Cryoport has supported eight commercial cell and gene therapies and 561 regenerative medicine clinical trials in more than 150 countries. 69 of these trials were in phase 3.
One of the leading leaders in its field, CRYOPDP aims to improve the health of people around the world by providing innovative global temperature-controlled logistics solutions to the clinical research and cell and gene therapy communities. CRYOPDP has facilities in 14 countries and operates in more than 150 countries.
Statements in this press release that are not purely historical, including statements regarding the intentions, hopes, beliefs, expectations, representations, projections, plans or predictions for the future of the Company , are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. from 1995. These forward-looking statements include, without limitation, those relating to the industry, activities, plans, strategy, acquisitions of the Company, including CRYOPDP and MVE Biological Solutions, financial results and condition. financial. It is important to note that the actual results of the Company could differ materially from those appearing in such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, product market trends, changes in cash flows of the Company, the risks of market acceptance and the risks of technical development. . The business of the Company could be affected by a number of other factors, including the risk factors discussed in the reports of the Company’s Securities and Exchange Commission (“SEC”), including but not limited to limit, the annual report of the Company on Form 10-K for the three and twelve months ended December 31, 2020 and any subsequent filing with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and the Company cautions investors not to place undue reliance on such forward-looking statements. Except as required by law, the Company disclaims all obligations and does not undertake to update or revise any forward-looking statements contained in this press release.